Crohn's Disease Clinical Trials in Atlanta, Georgia

10 studies are recruiting for crohn's disease in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

   The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinica…

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   Morehouse School Of Medicine ( Site 5071), Atlanta, Georgia

   Locations

   499 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06430801 on ClinicalTrials.gov

2. A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

   Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 month…

   Stage

   Phase 4

   Ages

   18 to 80

   Site

   Digestive Healthcare of Georgia, Atlanta, Georgia

   Locations

   101 in total

   Run by

   Takeda

   See if you can join NCT06581328 on ClinicalTrials.gov

3. A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

   This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).

   Stage

   Phase 2

   Ages

   18 to 85

   Site

   Atlanta Gastroenterology Specialists, PC, Atlanta, Georgia

   Locations

   225 in total

   Run by

   Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

   See if you can join NCT06226883 on ClinicalTrials.gov

4. A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

   The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Emory University, Atlanta, Georgia

   Locations

   85 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05923073 on ClinicalTrials.gov

5. A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

   Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study i…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Emory University Hospital, The Emory Clinic, Atlanta, Georgia

   Locations

   190 in total

   Run by

   Takeda

   See if you can join NCT06233461 on ClinicalTrials.gov

6. A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

   The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Contin…

   Stage

   Phase 3

   Ages

   2 to 19

   Site

   Emory University School of Medicine, Atlanta, Georgia

   Locations

   68 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT04844606 on ClinicalTrials.gov

7. A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

   Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn…

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Emory University, Atlanta, Georgia

   Locations

   81 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT05509777 on ClinicalTrials.gov

8. An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

   This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD. Study details include: The study duration may be up to 35 …

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   Atlanta Gastroenterology Associates-Site Number: 8400109, Atlanta, Georgia

   Locations

   301 in total

   Run by

   Sanofi

   See if you can join NCT07184931 on ClinicalTrials.gov

9. A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

   The study is an extension of two parent studies (MLN0002-3024 [NCT04779307] and MLN0002-3025 [NCT04779320]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.

   Stage

   Phase 3

   Ages

   2 and older

   Site

   Childrens Center For Digestive Healthcare, Atlanta, Georgia

   Locations

   98 in total

   Run by

   Takeda

   See if you can join NCT05442567 on ClinicalTrials.gov

10. A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

    This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.

    Stage

    Phase 2

    Ages

    18 to 80

    Site

    Mirador Therapeutics Selected Site, Atlanta, Georgia

    Locations

    66 in total

    Run by

    Mirador Therapeutics, Inc.

    See if you can join NCT07113522 on ClinicalTrials.gov